| Harry B Andrews, MD | |
|
2000 Mowry Ave, Fremont, CA 94538-1716 | |
| (510) 791-3430 | |
| Not Available |
| Full Name | Harry B Andrews |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 56 Years |
| Location | 2000 Mowry Ave, Fremont, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295865426 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | C31434 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carbon Health Medical Group Of California Pc | 9032340047 | 319 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659450955 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000757 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699885079 PECOS PAC ID: 1254244973 Enrollment ID: O20040113000784 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Entity Name | Emergency Physicians Associates Overhead Operating Account Dennis Belo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013969153 PECOS PAC ID: 0547230708 Enrollment ID: O20040727000859 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Entity Name | County Of Santa Clara |
|---|---|
| Entity Type | Part B Supplier - Other Medical Care Group |
| Entity Identifiers | NPI Number: 1629301346 PECOS PAC ID: 1254244973 Enrollment ID: O20110318000170 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Entity Name | Carbon Health Medical Group Of California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417294232 PECOS PAC ID: 9032340047 Enrollment ID: O20140314001276 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Entity Name | Carbon Health Primary Care Of California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972057990 PECOS PAC ID: 8628350626 Enrollment ID: O20170127001216 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Entity Name | Emergency Physicians Associates Fremont Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790250967 PECOS PAC ID: 8527303585 Enrollment ID: O20181219000821 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Harry B Andrews, MD 39159 Paseo Padre Pkwy, Suite 232, Fremont, CA 94538-1608 Ph: (510) 791-5376 | Harry B Andrews, MD 2000 Mowry Ave, Fremont, CA 94538-1716 Ph: (510) 791-3430 |
News Archive
A Rice University lab has won a prestigious National Institutes of Health grant to pursue gene-editing research it hopes will lead to a cure for sickle cell disease (SCD).
UK Government plans to remove logos from cigarette packaging risk "dangerous unintended consequences", including a price war that could actually lead to more smoking, a law expert at the University of Abertay Dundee has warned.
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, reported it recently filed the first module of its Pre-Marketing Approval (PMA) application to the United States Food & Drug Administration for its DPP® HIV 1/2 Screening Assay.
Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.
A new survey of 2,001 adults living with depression revealed that despite being diagnosed for an average of 12 years, many unknowingly took actions that could have sabotaged their chances of getting well. Furthermore, on average, it took about six years for respondents to seek diagnosis from a health care professional, suggesting these adults may have been coping with depression for as long as 18 years.
› Verified 8 days ago
Jerry Vann Martin, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2500 Mowry Ave, Suite 212, Fremont, CA 94538 Phone: 510-608-6174 Fax: 510-745-6435 | |
Lisa L. Minshall, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-795-3000 | |
Dr. Usha Rengarajan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3200 Kearney St, Fremont, CA 94538 Phone: 510-490-1222 | |
Dr. Shelly Verma, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Kearney St, Fremont, CA 94538 Phone: 510-490-1222 | |
Jamey J. Rock, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-795-3000 | |
Adele S Hultin, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-795-3000 | |
Stephen L Montgomery, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2000 Mowry Ave, Fremont, CA 94538 Phone: 510-791-3430 |